Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA.
Transplantation. 2024 Mar 1;108(3):585-587. doi: 10.1097/TP.0000000000004886. Epub 2024 Feb 21.
Hepatic ischemia-reperfusion injury remains a significant challenge in liver transplantation potentially leading to delayed graft function, primary nonfunction, and sometimes rejection. Understanding the underlying mechanisms and implementing mitigation strategies are essential for improving transplant outcomes and patient survival. A recent study published by Dery et al shows that alternative splicing of carcinoembryonic antigen-related cell adhesion molecule 1 regulated by hypoxia inducible factor 1 alpha under stress enhances hepatic ischemia tolerance in mice and humans. The authors identified a direct binding of hypoxia inducible factor 1 alpha to the promoter region of polypyrimidine tract-binding protein 1 splicing enzyme, resulting in carcinoembryonic antigen-related cell adhesion molecule 1-short induction and improved posttransplant outcomes. This study has notably elucidated a potential biomarker pertaining to the quality of liver transplant donor grafts.
肝缺血再灌注损伤仍然是肝移植的一个重大挑战，可能导致移植物功能延迟、无功能和排斥反应。了解潜在机制并实施缓解策略对于改善移植结果和患者生存率至关重要。最近由 Dery 等人发表的一项研究表明，缺氧诱导因子 1α在应激下调节癌胚抗原相关细胞黏附分子 1 的可变剪接增强了小鼠和人类的肝缺血耐受。作者发现缺氧诱导因子 1α与多嘧啶 tract 结合蛋白 1 剪接酶的启动子区域直接结合，导致癌胚抗原相关细胞黏附分子 1 短诱导和改善移植后结果。这项研究特别阐明了与肝移植供体移植物质量相关的潜在生物标志物。
